Purpose: The Singapore regulatory agency for health products (Health Sciences Authority), in performing active surveillance of medicines and their potential harms, is open to new methods to achieve this goal. Laboratory tests are a potential source of data for this purpose. We have examined the performance of the Comparison on Extreme Laboratory Tests (CERT) algorithm, developed by Ajou University, Korea, as a potential tool for adverse drug reaction detection based on the electronic medical records of the Singapore health care system.
| INTRODUCTION
Traditionally, spontaneous reporting systems (SRSs) have been the predominant data source for the detection of signals of adverse reactions. [1] [2] [3] This system, usually maintained by a government agency, receives suspected adverse drug reaction (ADR) reports submitted by health care professionals, pharmaceutical companies, and consumers. [1] [2] [3] With the expanding use of electronic medical records (EMRs) in recent years, the pharmacovigilance community has another potentially rich source of information for drug safety surveillance. 1, 3 The prospect of scanning EMRs is attractive, as it overcomes some of the limitations inherent in the SRS: (1) reliance mainly on voluntary reporting from its contributors, and susceptibility to under-reporting as well as over-reporting (eg, due to media interest), (2) incomplete or missing data, hindering causality assessment, and (3) difficulty in detecting duplicate reports. 1, 2 As EMRs are used for the clinical management of patients, they
constitute an information-rich database 3 of patients' demographics, medications, past medical history, laboratory results, etc, which are commonly missing from ADR reports. The records reflect actual clinical practice, allowing for a more complete benefit-risk assessment. For specific ADRs, mining of EMRs has the added advantage of applying a consistent phenotype definition, thus overcoming variations in diagnostic criteria by different clinicians.
However, unlike in SRS where a clinician has made a connection between the drug and an adverse event and files a report in a standardised format, much of EMR data are unstructured and housed in different databases. Preprocessing and data cleaning are required to extract and collate critical elements, such as drug exposure, concomitant medications, laboratory results, temporal relationships, and possible confounders. 1 The Comparison of Extreme Laboratory Test (CERT) algorithm was developed by Korean researchers who applied it to 10 different drugs over 10 years of EMR data from Ajou University Hospital. 4 For each patient exposed to a particular drug, the algorithm selects the extreme laboratory test result (minimum or maximum) among multiple laboratory values from each of the pre-and post-drug exposure periods. The CERT then determines whether a cohort of exposed patients demonstrates a significant change in abnormal laboratory values after drug exposure. As a regulatory agency seeking to build a toolkit of methods for active surveillance, the Health Sciences Authority (HSA), Singapore, sought to investigate the potential applicability of the CERT algorithm on the EMR in the Singapore health care system. The CERT algorithm had many desirable features that we were seeking, namely, a temporal relation between drug exposure and a laboratory abnormality, the flexibility to evaluate any drug and laboratory test, and good performance metrics. Utilisation of numerical laboratory values before and after drug exposure made it potentially more portable across national boundaries, regardless of the language of the country. 
| Selection of drugs for evaluation
Among the 10 drugs analysed in the original CERT paper, one drug (ketorolac) was not used at NUH, while 3 oncologic drugs (etoposide, fluorouracil, and methotrexate) were incompletely captured because oncologic drugs are mainly ordered and recorded in another database.
To have a direct head-to-head comparison of algorithm performance from the EMRs of two different health care institutions, we first analysed only 6 drugs described in the original CERT publication (round 1, Table 1 ).
In round 2, we investigated an additional 47 drugs (Table 2) .
Factors considered in drug selection were drug usage volume and the likelihood of the drug being started during hospitalisation. Drugs with high usage were prioritised to provide sufficient number of cases for analysis. We also included negative controls (chlorpheniramine, metronidazole, and risedronic acid) with no ADRs detectable by abnormal laboratory test results in the reference standard.
KEY POINTS
• The Comparison on Extreme Laboratory Tests (CERT) algorithm was implemented in the electronic medical records of a major tertiary hospital in Singapore, the National University Hospital (NUH).
• A modified version of CERT that requires a minimum of 400 cases to assess a drug-laboratory abnormality (CERT400) yielded higher positive predictive value and sensitivity.
• CERT400 demonstrated potential in detecting drug induced hepatic and renal toxicities, but limited utility in detecting ADRs associated with haematopoiesis and coagulation. (Table S2 ). As CERT uses laboratory abnormalities as a surrogate of ADRs, the ADRs were mapped to their respective laboratory abnormalities using the mapping table described in the original CERT paper. 4 In the original CERT algorithm, a case is defined when (1) the patient was prescribed the study drug at least once, and (2) Four variations of the original CERT algorithm were assessed on the set of 53 drugs (Table 3) : (1) limiting the period of observation to a defined period after the start of drug exposure, (2) limiting the post-drug exposure observation period to a defined number of laboratory tests, (3) taking an average of the two most extreme values instead of using only one extreme pre-and post-drug value, and (4) using the paired t test and nonparametric Wilcoxon's signed-rank test instead of paired t test and
McNemar's test. A fifth variation was also assessed post hoc in which only drug-AE pairs with a minimum of 400 cases were included. The rationale for these variations is presented in Section 4.
| Evaluation metrics
To evaluate the performance of CERT, we compared the drug-laboratory-abnormality pairs detected as significant signals by CERT with Variation 1: Limit the unit of observation to 12 days after drug exposure, which is the mean (7.1 d) plus 2 times the standard deviation (2.6 d) of the time from drug administration to the time the extreme post-drug laboratory value was taken for all true positive cases.
Variation 2: Limit the unit of observation to a maximum of (n + 2) laboratory test results for each encounter, where n is the number of laboratory tests before the drug was started.
Variation 3: Take the mean of the two most extreme values for both the pre-and post-drug periods, to minimise the possibility that a single extreme value, such as one caused by measurement error, would unduly influence the result. those identified in the reference standard. We then calculated the average positive predictive value (PPV), negative predictive value (NPV), sensitivity, and specificity for each drug based on laboratory abnormalities. The F score, which is the harmonic mean of PPV and sensitivity, is also reported (Table S3) . To contrast the results from different variations of the algorithm and get a pooled point estimate of the performance metrics and the 95% confidence interval, a random effects meta-analysis was performed to summarise a particular measurement of interest. Researchers may find this a useful resource for benchmarking other algorithms intended to identify ADRs from laboratory abnormalities.
| Creation of a reference standard
However, it is worthwhile to note that this reference standard is not a list of confirmed ADRs and is constantly being updated, and hence, some may consider it a "silver standard" rather than a "gold standard."
While UpToDate contains information from multiple sources about a drug's safety profile, ADRs that occur in specific population could be overlooked, and it may be incomplete for drugs that have only been recently approved.
3 | RESULTS
| Evaluation of CERT performance
The PPV, NPV, sensitivity, and specificity for round 1 (6 drugs) are summarised in Table 4A . When comparing the same drugs between NUH and Ajou University, our results showed similar PPV (55.6% vs 58%) and better specificity (64.3% vs 52.2%). We had lower NPV (56.2% vs 66.7%) and sensitivity (48.9% vs 71.3%).
When the CERT algorithm was evaluated on a larger set of 47 drugs (round 2) and benchmarked against an updated reference standard, PPV decreased to 48.5%, specificity was similar (65.2%), and sensitivity increased to 54.7%. Combining all 53 drugs evaluated in both rounds, overall PPV was 50.3%, specificity was 65.4%, and sensitivity was 54.1% for an F score of 52.1% (Table 4B ).
| Performance across different laboratory panels
Consistent with Ajou University's findings, most of the signals (93.6%) detected by CERT were from "haematopoiesis and coagulation,"
"hepatobiliary enzymes," and "renal function and urine tests," and these panels were associated with higher F scores compared to the remaining laboratory panels (Table 5 ). However, decreases in red blood cells, white blood cells, neutrophils, haematocrit, as well as haemoglobin were found for all of the drugs (with the exception of alendronic acid). Therefore, CERT may not be particularly discriminating for drug effects on those laboratory tests.
In "hepatobiliary enzymes," ALT and AST showed good PPV (92%, 87%) and specificity (83%, 83%), suggesting potential utility in detecting hepatotoxicity signals. The trade-off is the lower sensitivity (59%, 32%), potentially missing some valid signals. For the "renal function and urine tests," creatinine showed good PPV (80%) and specificity (93%) but very low sensitivity (11%). BUN had good PPV (77%) and sensitivity (62%). Many signals for increased potassium were detected, which were not reported in UpToDate. 5 The lipid and metabolism, hormones, and other panels also had high specificity (>87%) but low sensitivity (16%-17%). The PPV was also low, presumably because ADRs related to these abnormalities are rarer.
| Performance across different variations
Among the 4 initial variations, variations 1, 3, and 4 generally did not perform better than the original algorithm (Table 6 and Figure 1 ). Variation 2 had the best specificity (76.8%, Table 6 ). However, this was accompanied by a large drop in sensitivity (38.3%). When we examined the evaluation metrics as a function of number of cases, we noted that sensitivity increased above 50% when there were 400 or more cases (Figure 2 ). Increasing the minimum number of cases from two to 400 cases for each drug-laboratory abnormality pair appears to better control the number of false negatives, as expected from increased power of a larger sample size. Hence, we performed a post hoc analysis by imposing a threshold of 400 cases (variation 5). Variation 5, not surprisingly because of its post hoc nature, gave the best overall performance (PPV 53.9%, sensitivity 67.2%, F score 59.8%), and hereafter is referred to as CERT400.
| Negative controls
We tested CERT on 3 negative controls: chlorpheniramine, metronidazole, and risedronic acid. These drugs have no signals in the reference standard that would be indicative of laboratory abnormalities. Yet, for all 3 drugs, CERT detected decreases in red blood cell, white blood cell, neutrophil, haematocrit, haemoglobin, and protein, as well as increases in platelets and alkaline phosphatase (ALP). As noted above, most haematopoeisis tests returned positive results for all drugs, therefore these tests are of limited utility for ADR signal detection using CERT. Average performance for the 6 drugs from original paper. EMRs, new opportunities have arisen to mine these information-rich resources for safety signals. Here, we have shown that the CERT algorithm, which uses laboratory test data in a temporal relationship with drug exposure, can be implemented on EMR data in a health care institution from another country with a different population.
We have examined the performance of CERT for 53 drugs, of which direct comparison could be performed for 6 drugs in both countries.
We also investigated 5 variations of the original CERT algorithm and identified two that improve specificity and/or sensitivity.
The PPV of CERT was high for the liver enzymes ALT and AST and renal tests serum BUN and creatinine (92%, 87%, 77%, and 80%, respectively, Table 5 ); thus, a positive signal from CERT is likely to signify hepatic and renal toxicity. However, the aminoglycosides gentamicin and amikacin, which are known to be nephrotoxic, did not show a positive signal with either increased creatinine or BUN. This could be a result of close monitoring of renal function and/or therapeutic drug monitoring by clinicians to prevent any acute renal injury, thereby dampening the incidence of a well-known signal. The CERT did detect a signal of raised creatinine for other drugs with known nephrotoxic potential (eg, hydrochlorothiazide, ranitidine, and cefazolin), but sensitivity of the serum creatinine test was low (11%). However, sensitivity for BUN was much higher at 62%.
The CERT appears to be less discriminating for the haematopoiesis and coagulation panel, as nearly every drug had one or more signals in this panel. This may be more a reflection of the course of the disease or treatment. Similarly, the high number of false positives with potassium may be due to the high incidence of hyperkalaemia (up to 10%) in hospitalised patients, as many conditions can affect potassium levels (eg, transcellular shifts, impaired excretion, or increase in potassium intake). 5 Indeed, a major limitation of the CERT algorithm is the lack of adjustment for confounding factors. The CLEAR algorithm, 7 also
developed by the Ajou University group, controls for confounder effects with the use of matched controls having the same admitting In the original CERT algorithm, all tests in the pre-and post-drug exposure period were included. However, it was often the case that many more tests were ordered during the post-drug exposure period, which tends to inflate the chance finding of an abnormal result in the post-drug exposure period. By limiting the number of tests in the post-drug exposure period to two more than the number in the pre-drug exposure period (variation 2), we observed an increase in the specificity of CERT from 65.4% to 76.8%. The original CERT algorithm counted a drug-laboratory abnormality pair if there were at least two cases. We found that raising the minimum to 400 cases for each drug-laboratory abnormality pair (CERT400) helped to reduce the false negative rate, increasing the sensitivity from 54.1% to 67.2%. However, since the choice of 400 is based on results in these data, these estimates may be biased upwards. Although these performance metrics are not sufficiently high to solely rely on CERT400 for active surveillance, it promises to be a valuable addition to the toolkit for postmarket surveillance. A drug-laboratory abnormality pair identified by an automated CERT400 algorithm could then be further evaluated by other methodologies such as text mining of discharge summaries [8] [9] [10] to determine the validity of the signal. In the case of infrequently ordered laboratory tests, rarely used drugs, or newly approved drugs where usage has yet to pick up, the use of CERT400 may hinder detection of safety signals, since there may be insufficient cases to meet the minimum.
With the growth of electronic data in health care databases and linkages across multiple institutions, however, we anticipate that the rising volume of data will overcome the limitation of having this threshold of cases for evaluating the algorithm.
Other groups have been investigating a variety of data mining methodologies to query health records for identification of ADRs based primarily on clinical features. [11] [12] [13] [14] [15] [16] One notable effort is the Sentinel Initiative funded by the United States Food and Drug Administration. Specific queries of interest are submitted to the Sentinel coordinating center, which sends computer programs to data partners to extract and aggregate data on administrative and insurance claims data of over 180 million subjects. 17 The Sentinel group successfully identified intussusception after rotavirus vaccination in infants 13 and risk of coeliac disease in patients on long-term therapy with olmesartan 18, 19 from algorithms applied to their extensive databases.
The Observational Medical Outcomes Partnership investigated methods that relied primarily on diagnosis codes in administrative databases. 11, 20, 21 Our dataset had limited structured diagnostic coding, which made it challenging for us to explore algorithms that rely on codes such as ICD-9.
Methods using abnormal laboratory values for identifying ADRs have been investigated previously. In a study by Levy et al, 22 automatic laboratory signals were generated when a specific laboratory value met a predefined criteria and tested on a prospective cohort of 192 patients. A list of cases was generated for further manual review.
The false positive rate throughout the entire study period was 83%, which is a likely barrier to implementation. Ramirez et al implemented a prospective program based on automatic laboratory signals for 54 525 hospitalisations in Spain. 23 The algorithm flagged patients whose laboratory values met the criteria specified for 6 serious ADRs but did not include a temporal relationship with drug intake; hence, the cases needed to be manually reviewed to determine if the timing of drug intake could account for the abnormal laboratory values. The authors concluded that this was an intensive manual process requiring considerable effort.
Liu et al 3 aimed to have a more automated methodology that incorporated a temporal relationship with drug exposure. Abnormal laboratory results were correlated with specific drug administration by comparing the outcomes of drug-exposed and a matched unexposed group; higher thresholds for categorising a laboratory result as abnormal were used and a minimum of 25 cases was required. When benchmarked with two reference datasets (the same 10 drugs evaluated by Yoon et al or 9 other drugs), the reporting odds ratio (ROR) method performed best when applied to an EMR database containing 4 times more unique patients than the NUH database (PPV 77% and 58%, respectively, sensitivity 61% and 67%, respectively).
In summary, we have demonstrated the transferability of the CERT algorithm to a health care institution of another country. We have developed a reference standard of drug-laboratory abnormalities for 53 drugs based on the 2015 version of UpToDate to evaluate CERT on our data and which can also be used to benchmark other published algorithms. CERT400, a modification of CERT, which only accepts results generated from more than 400 drug-laboratory abnormality cases, gave the best overall performance with a PPV of 53.9% and sensitivity of 67.2% (F score 59.8%). High PPV for increased AST and ALT enzyme levels, BUN and serum creatinine suggests that CERT would be particularly useful for identifying drug-induced hepatic and renal toxicities. The ability of CERT400 to sift through a large volume of laboratory tests obtained before and after drug exposure and identify potential signals with reasonable PPV and sensitivity indicates that it will be a useful tool to add to a pharmacovigilance programme. 
